| Hypertension (label). Psychiatric uses are typically off-label (formulation- and population-dependent). View labelExact | Hypertension labeling commonly starts at 0.1 mg twice daily (morning and bedtime) (label). | Alpha-2 adrenergic agonist; reduces central sympathetic outflow (antihypertensive; also used off-label in psychiatry). | Hepatic metabolism (multiple pathways) | Single-dose range 12–16 h | No | | - Baseline and periodic blood pressure and heart rate, especially during titration or dose changes.
- Orthostasis, dizziness, and sedation; adjust dosing timing and review interacting medications if symptoms emerge.
- Renal impairment and medication adherence; missed doses can trigger rebound hypertension in some patients.
- Discontinuation plan documented in advance to reduce rebound hypertension and agitation risk.
| No | 2025-12-30 |
|---|
| Attention-deficit/hyperactivity disorder (ADHD) (extended-release formulation; product-dependent). View labelExact | Typically once daily. Morning dosing is common, but bedtime dosing can be considered when sedation is prominent.
Dosing typically starts low and titrates weekly as tolerated. Typical doses are 1–4 mg/day (product- and age-dependent). | Alpha-2A adrenergic agonist (non-stimulant ADHD medication). | CYP3A4 | Single-dose mean 17 h; Single-dose range 10–30 h | No | | - Baseline and periodic blood pressure and heart rate, especially during titration.
- Sedation, dizziness, and orthostasis are commonly monitored; dose timing and titration speed are adjusted as needed.
- Interacting medications (CYP3A4 inhibitors/inducers) and other sedatives are typically reviewed.
- Taper planning in advance can reduce rebound hypertension and irritability.
| No | 2025-12-29 |
|---|
propranololAdjunctive therapyBrands: INDERAL, INDERAL LA | Hypertension; angina pectoris; atrial fibrillation ventricular rate control; post-MI mortality reduction; migraine prophylaxis; essential tremor; hypertrophic subaortic stenosis; pheochromocytoma adjunct (label). View labelExact | Label dosing varies widely by indication (hypertension, arrhythmias, migraine prophylaxis). In psychiatric use, dose selection should be tied to the specific target symptom and the patient’s cardiopulmonary risk.
Performance anxiety (off label): low single doses taken before a time-limited event are common; start low and confirm tolerability with a trial dose (monitor heart rate, blood pressure, and dizziness). | Nonselective beta-adrenergic receptor blocker (beta-1/beta-2 antagonism). | CYP2D6, CYP1A2, CYP2C19, Glucuronidation | Single-dose range 3–6 h | No | — | - Check baseline heart rate, blood pressure, and asthma/COPD history before starting.
- Monitor bradycardia, hypotension, dizziness, and fatigue after dose changes.
- Reassess mood and sleep after initiation; discontinue or adjust if adverse effects outweigh benefit.
- Taper rather than stopping abruptly after sustained use, especially in coronary disease risk.
| No | 2025-12-29 |
|---|
| Anxiety symptoms (label); pruritus; pre/postoperative sedation (label varies by product). View labelExact | Anxiety/acute distress (off label patterns vary): 25–50 mg every 6–8 hours as needed; consider 10–25 mg starting doses in older adults or high fall risk. | First-generation antihistamine (H1 antagonist) with sedating and anxiolytic effects; anticholinergic/antiemetic properties. | Hepatic | No | | - Sedation, falls, and driving impairment are often reassessed after initiation and during dose changes—especially in older adults.
- Anticholinergic effects (constipation, urinary retention, confusion) are commonly monitored; total anticholinergic burden is minimized when possible.
- QT risk: QT-prolonging co-medications and electrolytes are typically reviewed, and baseline ECGs are often considered when risk factors stack.
- If use becomes frequent, the diagnosis is often revisited and plans may shift toward long-term anxiety treatment rather than continued PRN escalation.
| No | 2025-12-28 |
|---|